And that manpower comes when Flaskworks validation and ensuing commercial ramp comes. The initial price pop comes with approval but intrinsic value can’t really be determined by institutions until the manufacturing and reimbursement rates are more fully determined. Demand is not the issue, meeting it is. Even in the UK it’s obvious that Flaskworks must be “in range” before a likely acceptable reimbursement agreement to both sides gets put in place. The 18 month forward look pretty much points to this in my opinion otherwise there would have been a submission already sent in for reimbursement consideration based on the artisan method. The clear confirmation of this is that there are no plans to expand the artisan clean room signature. Best wishes.
LP knows an FDA rejection is the end of the company and in turn her financing and selling Advent. MHRA rejection lands with a little thud and she can continue printing shares to 2 billion. Nobody cares about MHRA. Nobody cared about it with the PIM designation in 2014 which did nothing for the stock but apparently allowed Advent to reap the rewards, and nobody cares now.
Market Data 
Markets 
